Skip to main content

Advertisement

Figure 4 | Critical Care

Figure 4

From: Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury

Figure 4

Risk for KDIGO stage 2 to 3 AKI (A) and MAKE 30 (B) as a function of urine [TIMP-2]·[IGFBP7]. Risk at each [TIMP-2]·[IGFBP7] value along the abscissa was calculated as follows: the number of samples positive for the endpoint that had [TIMP-2]·[IGFBP7] above the abscissa value divided by the total number of samples that had [TIMP-2]·[IGFBP7] above the abscissa value. Slightly more than 50% of the samples had a [TIMP-2]·[IGFBP7] value above 0.3 where risk began to elevate sharply and about 10% of the samples had a [TIMP-2]·[IGFBP7] value above 2.0 where risk almost doubled and quintupled for MAKE 30 and AKI, respectively. AKI, acute kidney injury; IGFBP7, insulin-like growth factor-binding protein 7; TIMP-2, tissue inhibitor of metalloproteinases-2.

Back to article page